34349553 33348190 33080342 34198049 34963185 34983073 35289881 33969261 - Search Results

Year	Number of Results
2020	2
2021	6
2022	2

1

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia.

Al Yami MS, Alzahrani MY, Alshehri AM, Alshaya OA, Alsubiae NS, Alharbi YM, Albaiahy LK, Aldeiban M, Alkuait HA, Alobaidi W, Aldawsari A, Almutairi NM, Alshibani M, Korayem GB, Alfayez OM, Almutairi AR, Almohammed OA. Al Yami MS, et al. Int J Gen Med. 2021 Jul 28;14:4031-4037. doi: 10.2147/IJGM.S322221. eCollection 2021. Int J Gen Med. 2021. PMID: 34349553 Free PMC article.

2

Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.

Guo JD, Hlavacek P, Rosenblatt L, Keshishian A, Russ C, Mardekian J, Ferri M, Poretta T, Yuce H, McBane R. Guo JD, et al. Thromb Res. 2021 Feb;198:163-170. doi: 10.1016/j.thromres.2020.11.039. Epub 2020 Dec 8. Thromb Res. 2021. PMID: 33348190 Free article.

3

Compared to randomized studies, observational studies may overestimate the effectiveness of DOACs: a metaepidemiological approach.

Safieddine M, Chapelle C, Ollier E, Ferdynus C, Bertoletti L, Mismetti P, Cucherat M, Laporte S. Safieddine M, et al. J Clin Epidemiol. 2021 Feb;130:49-58. doi: 10.1016/j.jclinepi.2020.10.013. Epub 2020 Oct 17. J Clin Epidemiol. 2021. PMID: 33080342

4

Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients.

Jin MC, Sussman ES, Feng AY, Han SS, Skirboll SL, Berube C, Ratliff JK. Jin MC, et al. Thromb Res. 2021 Aug;204:126-133. doi: 10.1016/j.thromres.2021.06.015. Epub 2021 Jun 27. Thromb Res. 2021. PMID: 34198049 Free article.

5

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.

Cohen AT, Sah J, Dhamane AD, Lee T, Rosenblatt L, Hlavacek P, Emir B, Delinger R, Yuce H, Luo X. Cohen AT, et al. Thromb Haemost. 2021 Dec 28. doi: 10.1055/s-0041-1740254. Online ahead of print. Thromb Haemost. 2021. PMID: 34963185 Free article.

6

Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.

Bertoletti L, Gusto G, Khachatryan A, Quignot N, Chaves J, Moniot A, Mokgokong R. Bertoletti L, et al. Thromb Haemost. 2022 Jan 4. doi: 10.1055/a-1731-3922. Online ahead of print. Thromb Haemost. 2022. PMID: 34983073 Free article.

7

Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.

Pawar A, Gagne JJ, Gopalakrishnan C, Iyer G, Tesfaye H, Brill G, Chin K, Bykov K. Pawar A, et al. JAMA. 2022 Mar 15;327(11):1051-1060. doi: 10.1001/jama.2022.1920. JAMA. 2022. PMID: 35289881

8

Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry.

Beyer-Westendorf J, Marten S, Tittl L, Naue C, Bornhäuser M. Beyer-Westendorf J, et al. TH Open. 2021 May 4;5(2):e143-e151. doi: 10.1055/s-0041-1728675. eCollection 2021 Apr. TH Open. 2021. PMID: 33969261 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results